SCHEMBL16775293

SCHEMBL16775293

CCc1cccc2c(-c3ccccc3C)cccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
CYP2A6 P11509 2/20 0.41
CYP1A2 P05177 1/20 0.41
GABRA1 P14867 2/20 0.40
GABRB2 P47870 2/20 0.40
ALDH1A1 P00352 2/20 0.40
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
AHR P35869 1/20 0.38
GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5599467 0.83 CSNK2A2 (0.49) BRD4GABRA1GABRB2TSHRSMN1; SMN2
SCHEMBL599157 0.83 CYP1A2 (0.62) CYP2A6CYP1A2GABRA1GABRB2ALDH1A1
SCHEMBL26835083 0.80 BRD4 (0.33) BRD4CYP2A6GABRA1GABRB2ALDH1A1
SCHEMBL3238496 0.80 GABRA1 (0.57) CYP1A2GABRA1GABRB2ALDH1A1
SCHEMBL29352142 0.78 CNR2 (0.39) GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL1132663 0.75 MYC (0.50) GABRA1GABRB2DHFRPTGS2
SCHEMBL5682891 0.75 GABRA1 (0.43) CYP1A2GABRA1GABRB2ALDH1A1
SCHEMBL30537735 0.75 GABRA1 (0.43) CYP1A2GABRA1GABRB2ALDH1A1
SCHEMBL7754391 0.74 CYP1A2 (0.62) CYP2A6CYP1A2GABRA1GABRB2ALDH1A1
SCHEMBL2996863 0.74 CYP2A6 (0.65) BRD4CYP2A6CYP1A2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof SEC61B, SEC61A1, SEC23A BRD4 3449/4885CYP2A6 2465/4885CYP1A2 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.